Nebenwirkungen · Flixabi
Flixabi 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 21–22
HOS-222791 · Präparat HOS-217086
21 Paediatric ulcerative colitis patients Overall, the adverse reactions reported in the paediatric ulcerative colitis trial (C0168T72) and adult ulcerative colitis (ACT 1 and ACT 2) studies were generally consistent. In C0168T72, the most common adverse reactions were upper respiratory tract infection, pharyngitis, abdominal pain, fever, and headache. The most common adverse event was worsening of ulcerative colitis, the incidence of which was higher in patients on the q12 week vs. the q8 week dosing regimen.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T12:15:00Z · SHA-256 01df900501649a0c225dc84d8f07b05b21b1d4deab3ad6c2da84a4b6879f8b57 · Passage 19bb12507f61cca04a788f651946e95dd1f0eeb007335ef20af86fd59b691d11 · Zeichen 28797–29313 im Abschnitt